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As patients decline from health to type 2 diabetes, glucose-stimulated
insulin secretion (GSIS) typically becomes impaired. Although
GSIS is driven predominantly by direct sensing of a rise in blood
glucose by pancreatic b-cells, there is growing evidence that
hypothalamic neurons control other aspects of peripheral glu-
cose metabolism. Here we investigated the role of the brain in
the modulation of GSIS. To examine the effects of increasing or
decreasing hypothalamic glucose sensing on glucose tolerance
and insulin secretion, glucose or inhibitors of glucokinase, re-
spectively, were infused into the third ventricle during intrave-
nous glucose tolerance tests (IVGTTs). Glucose-infused rats
displayed improved glucose handling, particularly within the
first few minutes of the IVGTT, with a significantly lower area
under the excursion curve within the first 10 min (AUC0-10). This
was explained by increased insulin secretion. In contrast, infusion
of the glucokinase inhibitors glucosamine or mannoheptulose
worsened glucose tolerance and decreased GSIS in the first
few minutes of IVGTT. Our data suggest a role for brain glucose
sensors in the regulation of GSIS, particularly during the early
phase. We propose that pharmacological agents targeting hypo-
thalamic glucose-sensing pathways may represent novel thera-
peutic strategies for enhancing early phase insulin secretion in
type 2 diabetes. Diabetes 61:321–328, 2012
The rise in prevalence of type 2 diabetes reflectsa primary medical challenge of the 21st century.The mechanisms underlying glucose homeosta-sis in general, and glucose-stimulated insulin
secretion (GSIS) in particular, are not fully understood. In
health, a rise in blood glucose triggers a biphasic pattern of
insulin response, consisting of a rapid (,10 min) first
phase and a less prominent but sustained second phase
(1). The precise mechanisms mediating the early phase of
the insulin response are unclear. Nevertheless, impaired
first-phase GSIS is a major pathological hallmark of the
early stages of type 2 diabetes (2), suggesting that this may
be an important determinant of the transition to diabetes
in at-risk subjects.
Pancreatic b-cells can directly sense changes in blood
glucose and alter insulin release as appropriate. In addition,
the pancreas has rich autonomic innervations, and a number
of experimental approaches have demonstrated that neural
inputs may modulate insulin release (3,4) via muscarinic
receptors or a-adrenergic signaling (5,6). A preponderance
of the neural inputs that influence pancreatic b-cell activity
emanate from the hypothalamus (5); however, the specific
nature of hypothalamic pathways regulating insulin secre-
tion is less clear.
In particular, hypothalamic melanocortin signaling (7–9)
and inflammation (10) have been implicated in the control
of insulin release. Additionally, there is increasing evidence
of a role for hypothalamic nutrient-sensing pathways in
the control of other facets of peripheral glucose metabo-
lism, in particular for hepatic glucose production (11,12). It
is therefore plausible that similar mechanisms might allow
central facilitation of insulin secretion in response to a rise
in blood glucose.
In order to control peripheral glucose metabolism, the
brain must first rapidly and accurately detect changes in
glucose availability. The hypothalamus contains glucose-
sensing neurons, although the mechanisms used to sense
glucose are not fully defined. However, some reports sug-
gest that these hypothalamic neurons may sense products
of glucose metabolism such as cellular ATP levels (11,13).
To be metabolized, glucose must first be phosphorylated
by hexokinases (HKs). The specialized low affinity HK
isozyme glucokinase (GK), thought to be central in pan-
creatic glucose sensing, may also play a key role in hy-
pothalamic glucose sensing (14). Accordingly, here we
investigated the effects of acute activation of hypotha-
lamic glucose sensing (by brain glucose infusion) or in-
hibition (using the competitive GK inhibitors glucosamine
[GSN] or mannoheptulose [MH]) on insulin secretion and
glucose handling during intravenous glucose tolerance
tests (IVGTT) in rats.
RESEARCH DESIGN AND METHODS
Animals. Healthy adult male Sprague Dawley rats ;250–350 g were used
throughout. For each study, the cohorts were matched for weight and ran-
domized into treatment groups. Procedures were approved in advance by both
a local university and a national ethical review process (U.K. Home Office
License held under the Animals [Scientific Procedures] Act). Chemicals were
from Sigma-Aldrich (Gillingham, U.K.) unless otherwise stated.
Surgical preparation. Under inhaled anaesthetic, rats underwent stereotaxic
insertion of a guide cannula into the base of the third ventricle (coordinates
from bregma: 2.2 mm posterior, 0.9 mm lateral, 8.4 mm below skull surface
angled at 5° to vertical toward the midline) and placement of jugular vein
catheter as previously described (15). Peri- and postoperative injectable an-
algesia and antibiotic were provided routinely, and only animals that had
regained preoperative body weight with no signs of infection or illness were
studied 1 week later.
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Effect of intracerebroventricular infusion of D-glucose versus urea
on glucose handling during IVGTT. Chronically catheterized intra-
cerebroventricular (ICV) and intravenous (IV) rats prepared as above were
brought to the study room on 2 subsequent days. Day 1 was for acclimatization,
with animals left undisturbed. On day 2, overnight-fasted rats were acclimatized
for 2 h before vascular catheters were opened and flushed and an ICV infusion
initiated. Nine milligrams of D-glucose (or equimolar urea) was delivered over
30 min (0.5 ml/min, primed for 3 min at 1.5 ml/min). Next, rats underwent
IVGTT with 0.35 g/kg delivered over 1 min (glucose dose was reduced by
9 mg in ICV glucose rats so that total glucose dose delivered was similar).
The glucose dose in these studies was selected to be toward the lower end of
the range used in rodent studies, given that we were anticipating an en-
hanced response with ICV glucose. Blood samples were collected over the
ensuing 60 min for plasma glucose and insulin assays. After 60 min, rats were
anesthetized deeply and brains perfused, removed, and examined to verify
correct cannula positioning.
Effect of ICV infusion of GSN or MH versus vehicle on glucose handling
during IVGTT.GSN and MH (CMS Chemicals, Abingdon, U.K.) were dissolved
in artificial extracellular fluid (aECF; CMA Microdialysis AB, distributed by
Linton Instrumentation, Diss, U.K.). Chronically catheterized rats were pre-
pared, acclimatized, and fasted overnight as above. Rats received ICV infusion
(0.3 ml/min, primed for 3 min at 0.9 ml/min) of GSN (75 nmol/min or 150 nmol/
min), MH (300 nmol/min), or vehicle (aECF). 90 min after the start of ICV
infusions, all animals received an IVGTT (0.5 g/kg glucose over 1 min) with
blood sampling as above. By design, the glucose dose in these studies was
higher than in the ICV glucose studies described above, given that we were
anticipating a reduced response with GK inhibition. At the end of the studies,
rats were anesthetized deeply and brains perfused with saline then fixative
and removed to verify correct cannula positioning.
Hormonal assays. Glucose was measured using a benchtop glucose analyzer
(Analox GM9 [glucose oxidase method]; Analox Instruments, London, U.K.)
and insulin by RIA (Linco).
Insulinogenic index. Insulinogenic index was calculated as the ratio of areas
under insulin and glucose excursion curves.
Assay of GK activity. Sections of hypothalami were dissected from brain
samples using the stereotaxic atlas of Paxinos and Watson as a reference guide
(16). Thereafter, hypothalamic and liver protein samples were prepared as
previously described with minor modification (17). In brief, tissues were ho-
mogenized in ice-cold lysis buffer (50 mM HEPES, 150 mM KCl, 5 mM MgCl2,
and 1 mM EDTA [pH 7.4], supplemented with 1 mM dithiothreitol, 1 mM
phenylmethylsulfonyl fluoride, and 10 mM leupeptin HCl) and centrifuged at
13,000 rpm for 20 min at 4°C. Supernatants were collected and stored at 280°C
for further analysis. HK and GK activity was assayed spectrophotometrically
(340 nm, room temperature, Beckmann DU-64 spectrophotometer) by cou-
pling glucose phosphorylation to a reporter assay, which oxidizes glucose-6-
phosphate to 6-phosphogluco-d-lactone with simultaneous reduction of NAD+
to NADH, as described previously (18). The reaction mixture in 1 mL final
volume contained 20 mM HEPES (pH 7.1), 25 mM KCl, 2 mM MgCl2, 1 mM
dithiothreitol, 1 mM NAD+, 1mM ATP, 10 units glucose-6-phosphate de-
hydrogenase from Leuconostoc mesenteroides, 1 mM 3-O-methyl N-acetyl GSN
(Axxora UK Ltd., Bingham, U.K.), 100 mL liver/hypothalamus protein extract,
and glucose in concentrations of 0.5 mM, 1 mM and 20 mM. In all assays for
GK activity, 3-O-methyl N-acetyl GSN was incorporated to inhibit N-acetyl
GSN kinase (19), except inhibition studies with MH and GSN. GK activity was
calculated by subtracting glucose phosphorylation at 0.5 mM (hypothalamus)
or 1 mM (liver) glucose from that measured at 20 mM glucose. Data were
analyzed by fitting sigmoidal curves to the dose-response studies by nonlinear
least square minimization method.
Determination of extent of GSN distribution following ICV infusion.
Nonfasted catheterized rats underwent 90 min ICV infusion of 150 nmol/
min GSN or aECF. Plasma samples were collected before and after ICV
infusion. After 90 min, rats were rapidly euthanized and their brains removed;
the hypothalamus, brain stem, and cortex were dissected rapidly and frozen
in liquid nitrogen. Samples were stored at –80°C before being analyzed.
Brain samples were homogenized in ice-cold lysis buffer, centrifuged at
13,000 rpm for 20 min at 4°C, and supernatants were collected for further
analysis.
GSN concentration in plasma and brain homogenate was assayed by high-
performance liquid chromatography–electrospray ionization–tandem mass
spectometry (HPLC-ESI-MS/MS). Analysis was performed using an Alliance
2695 chromatograph (Waters, Milford, MA) coupled with a triple-quadrupole
MS (Quattro LC; Micromass UK Ltd., Manchester, U.K.). Sample preparation
was optimized by a slight modification of a previously published method for
direct determination of GSN in plasma (20). Briefly, 45 mL of sample was
mixed with 5 mL of D-[1-13C] GSN as the internal standard; then, 25 mL of
trichloroacetic acid (200 g/L) were added to achieve protein precipitation.
3 mL of the supernatant was injected into the HPLC-ESI-MS/MS system.
A polymer-based amino column (5 mm, 2.0 mm i.d. 3 150 mm), supplied by
Showa Denko K.K. (Kanagawa, Japan), and mobile phase of 80:20 (volume for
volume) acetonitrile:10 mmol/L ammonium acetate (pH = 7.5) at 0.3 mL/min
flow rate were used. MS/MS detection, using ESI source in positive ionization,
was performed in multiple reaction monitoring mode, selecting the charge/
mass ratio transition 180→72 for GSN and charge/mass ratio181→73 for in-
ternal standard. The limit of quantification of the method was 0.28 mmol/L for
both rat plasma and brain homogenate. Matrix-matched standards were used
for calibration, obtaining good linearity up to 56 mmol/L (R2 $0.9937). For
calculating absolute concentrations, the density of brain tissue was assumed
to be 1.04 g/mL (21).
RESULTS
ICV infusion of D-glucose improved glucose handling
during IVGTT. We hypothesized that if the brain plays
a role in controlling GSIS, then increasing glucose levels in
the hypothalamus would lead to increased insulin secre-
tion. To investigate this, glucose was infused into the third
ventricle (ICV) of adult male rats for 30 min followed by an
IVGTT (0.35 g/kg) (Fig. 1A and B). ICV infusion of glucose
did not change systemic plasma glucose during the 30 min
infusion period (230 to 0 min). However, ICV glucose-
infused rats displayed improved glucose handling during the
first 10 min of the IVGTT, with a significantly lower (P,0.05)
area under the excursion curve (AUC0-10) relative to control
urea-infused animals (Fig. 1C and D).
Despite being exposed to equivalent or lower circulating
plasma glucose levels prior to and during IVGTT respec-
tively, plasma insulin levels in ICV glucose-infused rats were
significantly higher than controls, seemingly starting to rise
even before the delivery of an external glucose load (Fig.
1E). Insulin secretion between the start of the brain infusion
and the 10 min time point of the IVGTT (40 min total),
which was used as the cutoff between early and late-phase
insulin secretion, was significantly higher in ICV glucose-
infused rats (Fig. 1F). These data suggest that elevation of
hypothalamic glucose leads to a centrally driven insulin
secretory response.
ICV infusion of GSN impaired glucose handling and
insulin secretion during IVGTT. As a possible mecha-
nism underlying this observation, we examined the role
of hypothalamic GK-dependent sensing pathways in in-
sulin secretion in response to a systemic glucose load.
The competitive inhibitor of glucose phosphorylation,
GSN, has previously been shown to inhibit hepatic GK
(22). To confirm that GSN inhibits hypothalamic GK, we
first examined the effect of GSN on GK activity in hepatic
and hypothalamic protein preparations ex vivo. GK ac-
tivity was detectable in hepatic and hypothalamic protein
preparations from healthy Sprague Dawley rats ex vivo
(Fig. 2A and B). GSN dose-dependently inhibited rat liver
GK activity, with a half-maximal inhibitory concentration
(IC50) of 4.2 mM in the presence of 20 mM glucose
(Fig. 2C). GSN also dose-dependently inhibited hypotha-
lamic GK activity with an IC50 of 5.0 mM in the presence
of 20 mM glucose (Fig. 2D).
To determine the appropriate infusion regimen to be
used in subsequent studies and the sites and concen-
trations of GSN achieved, the extent of GSN distribution
following ICV infusion (150 nmol/min) was measured using
HPLC-ESI-MS/MS method. ICV GSN resulted in a marked
rise in hypothalamic GSN to levels of approximately 1 mM,
a modest rise in brain stem GSN levels (;15% of hypo-
thalamic levels), but did not alter cerebral cortex levels
(Table 1). Importantly, although our sensitive assay was
able to detect a small statistically significant change in
plasma values, levels of GSN in the blood stream remained
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at low micromolar levels, three orders of magnitude below
the levels required to inhibit GK.
Next, we examined whether hypothalamic levels of GSN
attained by 90 min ICV infusion (1 mM) would be sufficient
to inhibit hypothalamic GK activity. We aimed to measure
hypothalamic GK activity in the presence of 1 mM GSN in
vitro at a glucose concentration that is likely to simulate
ambient hypothalamic glucose levels during the IVGTT.
A concentration of 3 mM glucose was selected for in vitro
assays based on peak plasma glucose levels observed
during IVGTT (17 mM, Fig. 1) and on the fact that accepted
approximations of brain extracellular glucose concentrations
are roughly 20% of that of plasma glucose (23,24). GK rep-
resented ;5% of total hypothalamic glucose phosphorylation
activity at 3 mM glucose and was selectively inhibited by 1
mM GSN (reduced to 48.1 6 7.3% and total glucose phos-
phorylating activities was 97 + 1% of control, n = 3). These
kinetic studies suggested that ICV GSN in vivo, even at the
highest dose used, is unlikely to result in major spillage of
GSN outside the brain and that levels achieved might be
sufficient to inhibit, at least in part, hypothalamic GK activity.
We next investigated the effects of 90 min ICV infusion
of GSN at 75 and 150 nmol/min on plasma glucose and
insulin responses during IVGTT (0.5 g/kg—a higher dose
than that used in ICV-glucose studies above) (Fig. 3A). ICV
GSN significantly and dose-dependently impaired glucose
handling during IVGTT (Fig. 3B and C). Despite the higher
plasma glucose in the ICV GSN rats, insulin responses
FIG. 1. ICV infusion of glucose improved glucose handling during IVGTT. A and B: Schematic representation of experimental design. Vascular and
third ventricle (ICV) catheters were implanted on day 1. Rats were acclimatized to the study room on day 6 and fasted overnight from 1500 hrs on
day 6. On day 7, chronically catheterized rats underwent IVGTT (0.35 g/kg) preceded by ICV infusion of either 9-mg glucose or equimolar urea (n =
6–7) delivered over 30 min. C: ICV glucose rats showed reduced plasma glucose levels particularly during the first few minutes of IVGTT. D: In
particular, the AUC0-10 (plasma glucose) was significantly (P < 0.05) lower in ICV glucose-treated rats relative to control urea-treated rats. E and
F: Despite exposure to lower glycemia, plasma insulin responses were significantly greater in ICV glucose animals. Data are mean 6 SEM. *P <
0.05. (A high-quality color representation of this figure is available in the online issue.)
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were reduced, particularly during the first few minutes of
the glucose challenge, with peak and AUC0-10 insulin being
significantly lower in ICV 150 nmol/min GSN rats compared
with controls. As might be expected, ICV 75 nmol/min GSN
showed a pattern intermediate between the other two
groups. Insulinogenic index was significantly lower in both
ICV 150 nmol/min and 75 nmol/min GSN rats relative to
controls (Fig. 3D–F). Taken together, these data show that
third ventricle infusion of a low dose of a GK inhibitor, GSN,
predominantly distributed into the surrounding hypothala-
mus, impaired insulin secretion and glucose tolerance dur-
ing the first few minutes of an IVGTT in rats. Moreover,
these findings suggest a role for hypothalamic GK mediated
glucose sensing in the central regulation of GSIS.
FIG. 2. Ex vivo GK activity assays in protein preparations. A: Sigmoidal dependence of hepatic GK (n = 2) on glucose concentration. B: Glucose
increases hypothalamic GK activity. C and D: GSN dose dependently inhibits hepatic (n = 3–5) and hypothalamic (n = 3) GK ex vivo. E: MH dose
dependently inhibits hypothalamic GK ex vivo (n = 3), although with reduced potency as compared with GSN (IC50 =12 mM vs. 5 mM, MH vs. GSN,
respectively). **P < 0.01.
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ICV infusion of MH impaired glucose handling and
insulin secretion during IVGTT. A limitation of the
study above is that GSN has other biological actions in
addition to inhibiting glucose metabolism via GK, for in-
stance acting through the hexosamine pathway (25). The
study was repeated using MH, an alternative GK inhibitor
that is structurally unrelated to GSN and does not act
through the hexosamine pathway. Again, we first con-
firmed ex vivo that MH dose-dependently inhibited hypo-
thalamic GK (Fig. 2E). Given the lower potency of MH for
GK inhibition, a higher dose of MH was used for in vivo
studies. In keeping with an effect mediated by GK in-
hibition, ICV 300 nmol/min MH-treated rats displayed im-
paired glucose handling with a significantly higher AUC0-10
glucose relative to control rats (Fig. 4A and B). Consis-
tently, insulinogenic index was significantly lower in ICV
300 nmol/min MH rats relative to controls (Fig. 4C and D).
These findings further support a role for hypothalamic GK-
mediated glucose sensing in the regulation of GSIS in re-
sponse to an IV glucose challenge.
DISCUSSION
Although there is increasing evidence that hypothalamic
glucose sensing may contribute to the integrated control of
aspects of whole body glucose homeostasis (26) such as
hepatic glucose output (11,12) and hypoglycemia counter-
regulation (13), its role in the regulation of insulin secretion
has been less clear. Here, we provide the first direct
evidence that hypothalamic glucose sensors play a signifi-
cant role in the control of insulin secretion, one of the
most important systems in the maintenance of whole-body
glucose homeostasis.
Specifically, we observed that activation of hypotha-
lamic glucose sensing by ICV infusion of glucose improved
glucose handling and insulin secretion during IVGTT.
Furthermore, we demonstrated that pharmacological in-
hibition of hypothalamic glucose sensing by ICV infusion
of GK and HK inhibitors, GSN and MH, significantly im-
paired glucose handling and first-phase insulin secretion
during IVGTT. These data suggest a critical role for brain
glucose sensing in the regulation of the first phase of
pancreatic GSIS and in turn whole-body glucose tolerance.
Such a role is consistent with emerging evidence that hy-
pothalamic glucose sensors contribute to the integrated
control of peripheral glucose homeostasis (26).
As in humans, glucose infusion in rats elicits a biphasic
insulin response (27). In this study, we elected to use an
IVGTT rather than oral challenge because it allowed in-
vestigation of GSIS without a confounding effect from
incretins. Furthermore, IVGTT as a measure of insulin
secretion has been used successfully in rats. Similar to the
pattern seen in humans, both an early peak response
during the first few minutes after a glucose load and a later
sustained insulin release can be identified (28). Analogous
to humans, the early phase of insulin release is suppressed
in some rodent models of diabetes (29).
Although GSN and MH inhibit other HKs in addition to
inhibiting GK, the conditions of our studies suggest that
these effects are likely mediated via GK. Brain extracellular
glucose concentration is ;20% of that of plasma glucose
(23,24). Plasma glucose levels during IVGTT studies
attained peak values of approximately 17–20 mM (Figs. 1–3)
and 20% of these values are roughly 3–4 mM. However, it is
possible that glucose levels sensed by hypothalamic arcuate
nucleus (ARC) neurons may be higher than this because of
the proximity of the ARC to the median eminence, where
the blood-brain barrier is thought to be leaky (30). Since GK
is active in the hypothalamus at glucose concentrations
ranging from about 3 to 20 mM (31), it is better suited for
high capacity glucose phosphorylation necessary for glu-
cose sensing in this range of glucose concentrations than
other high affinity HKs (which are easily saturated at glu-
cose concentrations less than 500 mM). Our in vitro simu-
lation studies demonstrating that 1 mM GSN selectively
inhibits hypothalamic GK without interfering with other
HKs at 3 mM glucose further suggest that ICV GSN’s effects
during IVGTT are mediated via inhibition of hypothalamic
GK activity.
It is important to note that our studies do not permit us to
exclude a potential contribution from extrahypothalamic
brain regions influenced by third ventricle infusion in me-
diating centrally driven GSIS responses. However, given
that the relative levels of GSN achieved by our third
ventricle infusion in hypothalamus were approximately
5-fold higher than in the brain stem, the data suggest that
the hypothalamus received the highest concentration of GSN.
Furthermore, even though the data clearly demonstrate
a direct effect of brain glucose sensors on pancreatic GSIS,
the involvement of additional synergistic effects to im-
prove glucose handling by hypothalamic efferents, for
example, altering hepatic glucose output directly, cannot
be excluded. To delineate further the specific role of the
hypothalamus and specific hypothalamic subnuclei in the
effects of GSIS, localized injections of glucose and inhib-
itors of GK should be used. In addition, many elegant ge-
netic and pharmacogenetic tools are now available which will
enable further refined probing of the discrete role of spe-
cific chemically defined neurons, such as those expressing
the melanocortin neuropeptides in the ARC, in GSIS.
TABLE 1
GSN concentrations in brain and plasma









ICV 150 mol/min GSN 922 6 632* 142 6 119* 5 6 2 2 6 1 3 6 1*
ICV aECF 1 6 0 2 6 1 2 6 1 ND ND
Data are mean 6 SEM. GSN concentrations in brain areas (n =3–5) and plasma (n = 11) following 90-min ICV 150 nmol/min GSN or aECF
(vehicle). Chronically catheterized (jugular vein and third ventricle) adult male Sprague Dawley rats underwent 90-min ICV infusion of 150
nmol/min GSN or aECF, with blood sampling from ICV GSN rats at start and end of infusion. Following 90 min ICV infusions, animals were
killed and brains collected for ex vivo GSN assays. ND, no data. *P , 0.05 Mann-Whitney test for GSN vs. aECF and after vs. before ICV
infusion.
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Overall, our data support a role for hypothalamic glu-
cose sensing in the integrated control of peripheral glu-
cose homeostasis. In particular, our findings suggest a
novel model for the regulation of GSIS. We identified for
the first time that GK-dependent glucose phosphorylation in
the hypothalamus may play a facilitatory role in the regu-
lation of the first phase of insulin secretion in response to a
systemic glucose load. GK activators have been highlighted
as potential therapeutic candidates for type 2 diabetes (32),
in particular focusing on effects mediated by activation of
FIG. 3. ICV infusion of a GK inhibitor, GSN-impaired glucose handling, and insulin secretion during IVGTT. A: Experimental design. On day 7,
chronically catheterized (jugular vein and third ventricle) rats, which had been fasted overnight, underwent IVGTT (0.5 g/kg) preceded by 90-min
ICV infusion of either GSN at 75 nmol/min or 150 nmol/min, or vehicle (aECF) (n = 9–13). B: ICV GSN rats showed impaired glucose handling,
particularly during the first few minutes of IVGTT. C: The AUC0-10 (plasma glucose) increased significantly (P< 0.05) and dose-dependently in ICV
GSN-treated rats as compared with ICV vehicle-treated rats. D and E: In spite of higher plasma glucose levels in ICV GSN-infused rats, plasma
insulin levels were reduced significantly and dose-dependently relative to vehicle-treated rats. Insulinogenic index was also significantly reduced
by both ICV 150 and 75 nmol/min treatment as compared with ICV aECF. Data are mean 6 SEM. *P < 0.05; **P < 0.01 (A high-quality color
representation of this figure is available in the online issue.)
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hepatic and pancreatic GK. Our data suggest that a further
beneficial action might be targeting GK-mediated glucose
sensing in the hypothalamus.
In conclusion, our findings delineate a novel central
mechanism in the control of glucose-stimulated insulin
release and suggest that this may offer a future thera-
peutic target for improving glycemic control in type 2
diabetes.
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